RadNet Stock - analyst consensus and sector view on imaging group
19.06.2026 - 22:01:14 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 19:56 UTC. Details in the imprint.
RadNet (US75025X1000) operates one of the largest networks of outpatient diagnostic imaging centers in the United States. With no fresh market-moving headlines today, investors are focusing on analyst estimates, recent earnings trends and how the stock compares with other healthcare service names.
Background and price data on RadNet stock
Key figures, news and consensus data on RadNet stock help investors understand how the imaging specialist is positioned in the US healthcare services market.
What analysts currently expect
RadNet last reported quarterly results on 05/09/2024, posting first-quarter revenue of about $431 million, up roughly 10% year-on-year, and a small net loss as the company continued to invest in AI and network expansion, according to its IR release dated 05/09/2024.
Data from consensus aggregators shows that several covering analysts maintain positive views, with most ratings clustered around Buy or Overweight and only a minority at Hold. Earnings estimates for 2024 and 2025 generally point to continued revenue growth and improving margins if volumes remain robust.
How RadNet compares with peers
In the broader diagnostic imaging and outpatient services space, investors often compare RadNet with names such as Akumin, Envision Healthcare’s imaging activities before restructuring, or diversified hospital operators that run imaging departments. These peers face similar reimbursement, labor and volume trends, even if their business mixes differ.
Against this backdrop, RadNet’s focus on outpatient centers and radiology-specific workflows offers more targeted exposure than large hospital chains. Market data from trading platforms shows RadNet shares have been more volatile than some larger healthcare providers, reflecting both growth potential and higher execution risk in its roll-up and AI strategies.
How the company makes money
RadNet generates most of its revenue by operating outpatient diagnostic imaging centers that offer MRI, CT, PET/CT, X-ray, ultrasound and mammography services for referred patients. The company also develops radiology-focused IT and AI solutions, including breast cancer screening tools, to support its own network and external customers.
Where the stock trades today
RadNet stock (US75025X1000) trades on the Nasdaq at around $X.XX as of 06/19/2026, 19:30 UTC.
Key facts on RadNet stock
- Company: RadNet Inc.
- ISIN: US75025X1000
- WKN: A0Q7EA
- Ticker: RDNT
- Venue: Nasdaq
- Price (as of 06/19/2026, 19:30 UTC): X.XX USD
- Market cap: [market cap] USD (as of 06/19/2026)
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: not a member of major headline indices such as the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
